<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-107475" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pentoxifylline</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Annamaraju</surname>
            <given-names>Pavan</given-names>
          </name>
          <aff>Loma Linda University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Baradhi</surname>
            <given-names>Krishna M.</given-names>
          </name>
          <aff>University of Oklahoma</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pavan Annamaraju declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Krishna Baradhi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-107475.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Pentoxifylline is a&#x000a0;xanthine derivative used in the management of peripheral vascular disease. As a phosphodiesterase inhibitor (PDEi), the drug improves blood flow by reducing viscosity and enhancing red blood cell flexibility. This activity outlines the mechanism of action, administration, indications, off-label uses,&#x000a0;adverse drug reactions, and&#x000a0;contraindications. Additionally, this activity reviews the pharmacokinetics, monitoring strategies, and clinical toxicology of pentoxifylline. Given the complexity of its pharmacological actions and potential interactions with other medications,&#x000a0;clinicians must be well-versed in prescribing pentoxifylline appropriately and monitoring patients for adverse effects.</p>
        <p>Clinicians should weigh the risks and benefits before prescribing pentoxifylline, with pharmacists playing a pivotal role in dose optimization to minimize adverse reactions. Empowering&#x000a0;prescribing clinicians is essential for optimizing patient care and preventing adverse outcomes in associated cardiovascular conditions.&#x000a0;Through interprofessional collaboration,&#x000a0;teams can leverage collective expertise to optimize pentoxifylline therapy outcomes, improving patient well-being and healthcare delivery as a result.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for pentoxifylline in the management of peripheral vascular disease.</p></list-item><list-item><p>Differentiate between common adverse reactions associated with pentoxifylline and other medications used&#x000a0;for similar conditions.</p></list-item><list-item><p>Assess patient response to pentoxifylline&#x000a0;therapy and adjust&#x000a0;the regimen as necessary for optimal outcomes.</p></list-item><list-item><p>Implement effective collaboration among interprofessional team members to improve treatment efficacy for patients who might benefit from pentoxifylline.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=107475&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=107475">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-107475.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Pentoxifylline is a vasoactive agent that improves blood flow by reducing viscosity.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Pentoxifylline is FDA-approved for the symptomatic treatment of claudication.&#x000a0;The drug is inferior to cilostazol or a supervised exercise program. Claudication is associated with chronic occlusive peripheral vascular disorders of the lower extremities.<xref ref-type="bibr" rid="article-107475.r1">[1]</xref><xref ref-type="bibr" rid="article-107475.r2">[2]</xref>&#x000a0;The drug may improve tissue perfusion in such patients by enhancing blood flow and alleviating ischemic pain signs and symptoms.<xref ref-type="bibr" rid="article-107475.r3">[3]</xref>&#x000a0;Although this medication can alleviate symptoms, it is not meant to substitute standard treatments for peripheral vascular disease. Moreover, the American College of Chest Physicians and American Heart Association/American College of Cardiology (AHA/ACC) guidelines do not endorse pentoxifylline as a definitive treatment of peripheral arterial disease.<xref ref-type="bibr" rid="article-107475.r4">[4]</xref>&#x000a0;However, a network meta-analysis concluded that pentoxifylline is effective for the symptomatic treatment of intermittent claudication.<xref ref-type="bibr" rid="article-107475.r5">[5]</xref><xref ref-type="bibr" rid="article-107475.r6">[6]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Venous ulcers:</bold> A Cochrane review found pentoxifylline effective in treating venous ulcers with or without compression therapy compared to placebo or no treatment.<xref ref-type="bibr" rid="article-107475.r7">[7]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Severe alcoholic hepatitis:</bold> Pentoxifylline is a tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) inhibitor, a major cytokine in the pathogenesis of alcoholic hepatitis. In a meta-analysis, researchers noted pentoxifylline was superior to placebo in preventing fatal hepatorenal syndrome without any survival benefit in&#x000a0;1 month.&#x000a0;Pentoxifylline is a suitable treatment for severe alcoholic hepatitis when contraindications to corticosteroids exist.<xref ref-type="bibr" rid="article-107475.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Osteoradionecrosis:</bold> Liquid pentoxifylline and vitamin E are promising as alternative formulations for patients with dysphagia or enteric feeding, offering clinical benefits for established osteoradionecrosis and prophylaxis before dental procedures. Retrospective data reveal favorable outcomes, with a high proportion of surgical sites healing completely and minimal reported&#x000a0;adverse effects. More research is needed as the metanalysis findings provided insufficient evidence.<xref ref-type="bibr" rid="article-107475.r9">[9]</xref><xref ref-type="bibr" rid="article-107475.r10">[10]</xref><xref ref-type="bibr" rid="article-107475.r11">[11]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-107475.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Pentoxifylline and&#x000a0;the metabolites decrease blood viscosity and improve blood flow and peripheral tissue oxygenation. The precise mechanism of action&#x000a0;that leads to symptom improvement remains yet to be determined. However, several pathways are likely involved.</p>
        <list list-type="bullet">
          <list-item>
            <p>Pentoxifylline increases red blood cell flexibility by increasing erythrocyte ATP and cyclic nucleotide levels.&#x000a0;This reduces blood viscosity by decreasing erythrocyte aggregation and stimulating fibrinolysis to reduce plasma fibrinogen concentrations.&#x000a0;All these effects enhance the ability of blood to flow through peripheral vessels (hemorheological action).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pentoxifylline is a PDEi. By blocking the membrane-bound phosphodiesterase,&#x000a0;pentoxifylline increases the concentration of cyclic AMP.&#x000a0;The drug&#x000a0;also inhibits thromboxane synthesis and increases prostacyclin synthesis. These actions result in reduced platelet aggregation. Further, pentoxifylline has demonstrated decreased adhesion of platelets to the vessel wall in patients with circulatory disorders.<xref ref-type="bibr" rid="article-107475.r12">[12]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pentoxifylline exerts vasodilation in the skeletal muscle vascular bed by inhibiting PDE and increasing the cAMP.<xref ref-type="bibr" rid="article-107475.r13">[13]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pentoxifylline inhibits the leukocyte-derived free radicals generated during peripheral ischemia in patients with peripheral vascular disease.&#x000a0;This has been shown to reduce the impairment of the filterability rate of unfractionated leucocytes, limiting ischemia-related tissue damage.<xref ref-type="bibr" rid="article-107475.r14">[14]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pentoxifylline has immunomodulatory effects. The drug improves leukocyte deformability and chemotaxis,&#x000a0;leading to depressed&#x000a0;neutrophil degranulation, decreased endothelial leukocyte adhesion, and lowered sensitivity of leukocytes to cytokines. Pentoxifylline can inhibit the production of inflammatory cytokines.<xref ref-type="bibr" rid="article-107475.r15">[15]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Several animal studies have demonstrated the role of pentoxifylline in attenuating ischemia-reperfusion injury, drug-induced nephrotoxicity, infection, and inflammation.</p>
        <list list-type="bullet">
          <list-item>
            <p>Pentoxifylline minimized the ischemia-related tissue damage to the intestinal mucosa during reperfusion in Wistar rats.<xref ref-type="bibr" rid="article-107475.r16">[16]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Treatment with pentoxifylline attenuated methotrexate-induced renal tissue injury cell death and suppressed the elevation of blood urea nitrogen and creatinine levels in Wistar rats.<xref ref-type="bibr" rid="article-107475.r17">[17]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pentoxifylline exerts a beneficial, gastroprotective effect against stress-induced gastric lesions by improving gastric microcirculation in Wistar rats. This effect is likely due to the enhanced nitric oxide synthase (NOS) activity, local action of the nitric oxide, and attenuation of oxidative metabolism and proinflammatory cytokines.<xref ref-type="bibr" rid="article-107475.r18">[18]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In a murine macrophage cell line model, pentoxifylline reduced TNF protein levels by inhibiting TNF mRNA transcription in response to bacterial infection.<xref ref-type="bibr" rid="article-107475.r19">[19]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pentoxifylline minimized liver damage induced by ischemia-reperfusion in albino rats.<xref ref-type="bibr" rid="article-107475.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>Multiple clinical studies have demonstrated the role of pentoxifylline's anti-inflammatory, anti-fibrotic, and hemorheological properties in various disease states.</p>
        <list list-type="bullet">
          <list-item>
            <p>In a prospective randomized study, pentoxifylline demonstrated a statistically significant reduction in hemolysis during cardiopulmonary bypass compared to the control sample of patients.<xref ref-type="bibr" rid="article-107475.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In a prospective, placebo-controlled, randomized clinical trial of coronary artery bypass graft candidates with an ejection fraction lower or equal to 30%, pretreatment with pentoxifylline for&#x000a0;3 days before the procedure was associated with reduced tumor necrosis factor-&#x003b1; level, interleukin-6 level, improved left ventricular ejection fraction, decreased intensive care unit stay, ventilation time, and need for inotropic agents and blood transfusion.<xref ref-type="bibr" rid="article-107475.r22">[22]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In patients with type-2 diabetic nephropathy on ACEi or angiotensin receptor blockers (ARBs) for more than&#x000a0;6 months and on conventional treatment, the addition of pentoxifylline therapy reduced proteinuria and improved glucose control and insulin resistance without a significant change of serum TNF-&#x003b1; in patients.<xref ref-type="bibr" rid="article-107475.r23">[23]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Oral administration of pentoxifylline can improve cerebral blood flow in patients with cerebrovascular disease.<xref ref-type="bibr" rid="article-107475.r24">[24]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In a double-blind placebo-controlled trial, administering pentoxifylline to patients with multi-infarct dementia showed intellectual and cognitive function improvements.<xref ref-type="bibr" rid="article-107475.r25">[25]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Pentoxifylline is rapidly and completely absorbed in the gastrointestinal (GI) tract after oral administration.&#x000a0;The drug is usually recommended with meals (food or milk) to minimize&#x000a0;GI irritation. It is usually a sustained-release tablet with an early peak plasma pentoxifylline concentration&#x000a0;2 to&#x000a0;3 hours postadministration.</p>
        <p><bold>Bioavailability:</bold> 20% to 30%, because of a high first-pass clearance.<xref ref-type="bibr" rid="article-107475.r26">[26]</xref><xref ref-type="bibr" rid="article-107475.r27">[27]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;Erythrocytes and the liver extensively metabolize pentoxifylline to its active metabolites (M1).<xref ref-type="bibr" rid="article-107475.r28">[28]</xref></p>
        <p><bold>Excretion:</bold>&#x000a0;Pentoxifylline and its metabolites are primarily eliminated by the kidneys and less than 5% by feces. On the other hand, its key metabolites are also secreted in breast milk. The half-life of pentoxifylline is about 0.4 to 0.8 hours, and&#x000a0;the metabolites are about 1 to 1.5 hours.</p>
      </sec>
      <sec id="article-107475.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Generic name:&#x000a0;Pentoxifylline</p>
        <p>Chemical name:&#x000a0;3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione.</p>
        <p>Solubility:&#x000a0;Pentoxifylline is soluble in chloroform, methanol, and water.</p>
        <p>Dosage form:&#x000a0;Pentoxifylline is available as a 400 mg extended-release oral tablet.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>Intermittent claudication: 400 mg orally 3 times per day with meals. Reduce the dose to 400 mg twice daily if&#x000a0;GI intolerance is observed.<xref ref-type="bibr" rid="article-107475.r2">[2]</xref><xref ref-type="bibr" rid="article-107475.r28">[28]</xref></p>
        <p>
<bold>Off-Label Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe alcoholic hepatitis: 400 mg orally 3 times daily for&#x000a0;4 weeks.<xref ref-type="bibr" rid="article-107475.r29">[29]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Venous leg ulcer: 400 mg orally 3 times daily.<xref ref-type="bibr" rid="article-107475.r30">[30]</xref><xref ref-type="bibr" rid="article-107475.r7">[7]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of neuropathic pain secondary to diabetic neuropathy: 400 mg orally 3 times daily after meal.<xref ref-type="bibr" rid="article-107475.r31">[31]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of Kawasaki disease: The recommended dosage is 20 mg/kg/day to reduce the prevalence of coronary artery lesions.<xref ref-type="bibr" rid="article-107475.r32">[32]</xref><xref ref-type="bibr" rid="article-107475.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pentoxifylline has been used in isolated case reports for specific indications. In Behcet syndrome-related ocular disease, a 2-week regimen of 600 mg per oral has been used. For prophylaxis against acute claudication in sickle cell disease, a dosage of 400 mg per oral&#x000a0;3 times daily after meals has been suggested. Further research is needed to validate its efficacy and safety in these contexts.<xref ref-type="bibr" rid="article-107475.r34">[34]</xref><xref ref-type="bibr" rid="article-107475.r35">[35]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p><bold>Hepatic impairment:</bold> Pentoxifylline should be used with caution in mild to moderate liver impairment as it may cause an increase in the exposure of pentoxifylline and its active metabolite. The use of pentoxifylline should be avoided in severe hepatic impairment.</p>
        <p><bold>Renal impairment:</bold> In patients with renal impairment and creatinine clearance (CrCl) below 30 mL/min, the dose of pentoxifylline should be reduced to 400 mg/day.</p>
        <p><bold>Pregnancy considerations:</bold> Pentoxifylline crosses the placenta in mice; evidence in humans is lacking. Therefore, it is not recommended for pregnant women unless the benefits outweigh the risks.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Caution is advised when administering pentoxifylline to breastfeeding mothers, as pentoxifylline and its metabolites can be secreted in milk.&#x000a0;Although evidence indicates that&#x000a0;the drug is generally safe for breastfed infants, particularly those older than&#x000a0;2 months, it is advised to carefully consider whether to continue nursing or cease the medication, weighing the drug's significance for the mother.<xref ref-type="bibr" rid="article-107475.r36">[36]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>Pentoxifylline in patients aged below 18 is not advised because its safety profile and efficacy have not yet been established.</p>
        <p><bold>Older&#x000a0;patients:&#x000a0;</bold>The older patients exhibit higher peak plasma levels of the metabolites of pentoxifylline, leading to potential toxicity. Starting the pentoxifylline dosage at a lower level is recommended, considering polypharmacy and impaired renal/hepatic/cardiac function.</p>
      </sec>
      <sec id="article-107475.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effect of pentoxifylline is nausea and vomiting. Other common adverse drug reactions are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>GI&#x000a0;system: Abdominal discomfort, bloating, and diarrhea</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cardiovascular system: Flushing; other infrequent side-effects are chest pain, arrhythmias, hypertension, dyspnea, tachycardia, and hypotension.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Central nervous system: Dizziness, headache<xref ref-type="bibr" rid="article-107475.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Antihypertensive agents:</bold> Pentoxifylline has been used with antihypertensive drugs, including beta blockers and diuretics.&#x000a0;Some patients treated with pentoxifylline and nifedipine or captopril have shown slight reductions in blood pressure.<xref ref-type="bibr" rid="article-107475.r37">[37]</xref><xref ref-type="bibr" rid="article-107475.r38">[38]</xref>&#x000a0;Periodic monitoring of systemic blood pressure in patients receiving concurrent antihypertensive therapy with pentoxifylline is recommended. If necessary, consider adjusting the dosage of the antihypertensive agents.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Oral hypoglycemic drugs:</bold> In animal studies, pentoxifylline enhances the anti-glycemic action of antidiabetic agents such as glibenclamide or metformin. Pentoxifylline has been demonstrated to inhibit ATP-sensitive K channels similar to glyburide in diabetic rats.<xref ref-type="bibr" rid="article-107475.r39">[39]</xref>&#x000a0;A dose reduction of anti-glycemic agents and glucose monitoring is recommended.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Antiplatelet drugs:</bold> Pentoxifylline can increase the risk of bleeding in patients taking warfarin or antiplatelet agents. Monitoring PT/INR is recommended.&#x000a0;The study has demonstrated that in patients with chronic kidney disease, the administration of pentoxifylline, particularly at daily doses exceeding 800 mg, requires monitoring for bleeding risk, especially in patients with a history of ischaemic stroke and regular aspirin use.<xref ref-type="bibr" rid="article-107475.r40">[40]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Theophylline:</bold> Pentoxifylline increases the plasma levels of theophylline by decreasing the clearance of theophylline, necessitating therapeutic drug monitoring.<xref ref-type="bibr" rid="article-107475.r41">[41]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Ketolorac:</bold> Administering ketorolac concurrently with pentoxifylline should be avoided due to increased bleeding risk.<xref ref-type="bibr" rid="article-107475.r42">[42]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-107475.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The following are contraindications to&#x000a0;pentoxifylline:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients with&#x000a0;recent retinal or cerebral hemorrhage</p>
          </list-item>
          <list-item>
            <p>Allergy to xanthine derivatives, eg, caffeine, theophylline, theobromine<xref ref-type="bibr" rid="article-107475.r43">[43]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute myocardial infarction or severe coronary disease due to increased risk of myocardial demand</p>
          </list-item>
          <list-item>
            <p>Severe liver disease (Child-Pugh class C) or cirrhosis</p>
          </list-item>
          <list-item>
            <p>Anaphylaxis due to pentoxifylline has been reported. Do not administer pentoxifylline in patients with a history of anaphylaxis.<xref ref-type="bibr" rid="article-107475.r44">[44]</xref></p>
          </list-item>
          <list-item>
            <p>Patients receiving pentoxifylline, particularly those with a history of peptic ulceration, recent surgery, or at risk of bleeding, especially in individuals with chronic kidney disease, should undergo regular assessments for signs of bleeding, including monitoring hematocrit and hemoglobin levels.<xref ref-type="bibr" rid="article-107475.r40">[40]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-107475.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Older patients are at higher risk of&#x000a0;adverse effects from pentoxifylline. Careful monitoring of blood pressure and glucose levels is recommended when administering pentoxifylline to patients on antihypertensive and antidiabetic medications. They are at high risk for hypotension, falls, and hypoglycemia. Patients with liver disease should also&#x000a0;undergo&#x000a0;follow-up with periodic laboratory monitoring. Patients at increased risk of bleeding should be advised of potential signs and symptoms of bleeding and monitored with periodic laboratory data, including hematocrit and hemoglobin.&#x000a0;Clinicians should exercise caution with cardiac arrhythmias and low blood pressure patients. Ankle-brachial index (ABI), pain-free walking distance, and maximum walking distance should be monitored for patients with peripheral arterial disease.<xref ref-type="bibr" rid="article-107475.r5">[5]</xref><xref ref-type="bibr" rid="article-107475.r45">[45]</xref></p>
      </sec>
      <sec id="article-107475.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p><bold>Signs and Symptoms of Overdose</bold>&#x000a0;</p>
        <p>Reports of adverse effects of pentoxifylline are apparent in patients on chronic hemodialysis.<xref ref-type="bibr" rid="article-107475.r46">[46]</xref>&#x000a0;Metabolic acidosis, hypokalemia, and arrhythmias are the primary symptoms of pentoxifylline overdose. Additionally, oliguria, cardiovascular collapse, and altered consciousness, including delirium, agitation, and coma, have been reported.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>No reported antidote is available for this medication. The prescriber should discontinue the drug in suspected cases of toxicity. The symptomatic treatment includes administering IV fluids, NaHCO<sub>3</sub> supplementation, and norepinephrine infusion. In cases of significant overdose, consideration should be given to gastric lavage. Extracorporeal elimination is not currently recommended; however, it may be a viable option for patients with severe metabolic acidosis or impaired kidney function.<xref ref-type="bibr" rid="article-107475.r47">[47]</xref><xref ref-type="bibr" rid="article-107475.r48">[48]</xref></p>
      </sec>
      <sec id="article-107475.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clinicians should prescribe pentoxifylline after considering the risk-benefit analysis. Pharmacists play a crucial role in determining the proper dose of medication to minimize adverse drug reactions. A retrospective cohort study analyzed the association between a specialist clinical pharmacist collaborating with medical staff and prescribing practices in peripheral arterial disease. The study compared&#x000a0;2 patient groups admitted to a vascular surgery unit in 2007 (control group) before the introduction of a comprehensive clinical pharmacy service and in 2009 (comparison group) after its implementation. Data was collected from electronic reports and medical records, revealing significant improvements in medication initiation and risk factor management with the inclusion of a clinical pharmacist in the collaborative healthcare team.<xref ref-type="bibr" rid="article-107475.r49">[49]</xref>&#x000a0;</p>
        <p>The contributions of both nurses and dieticians are essential to educating patients, ensuring medication adherence, and making necessary adjustments to mitigate risk factors associated with atherosclerotic disease. Complex cases of peripheral vascular disease should be managed in consultation with vascular surgeons. In overdose, emergency medicine&#x000a0;clinicians should rapidly stabilize patients. Significant overdose may require MICU admission under the supervision of critical care. If the overdose is intentional, close consultation with a psychiatrist is needed. An interprofessional team approach between clinicians (MDs, DOs, NPs, PAs), pharmacists, nurses, and specialists is required to optimize patient outcomes related to pentoxifylline pharmacotherapy.</p>
      </sec>
      <sec id="article-107475.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=107475&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=107475">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/107475/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=107475">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-107475.s11">
        <title>References</title>
        <ref id="article-107475.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Girolami</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bernardi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Prins</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Ten Cate</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Hettiarachchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Prandoni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Girolami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>B&#x000fc;ller</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis.</article-title>
            <source>Arch Intern Med</source>
            <year>1999</year>
            <month>Feb</month>
            <day>22</day>
            <volume>159</volume>
            <issue>4</issue>
            <fpage>337</fpage>
            <page-range>337-45</page-range>
            <pub-id pub-id-type="pmid">10030306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aviado</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects.</article-title>
            <source>Pharmacotherapy</source>
            <year>1984</year>
            <season>Nov-Dec</season>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>297</fpage>
            <page-range>297-307</page-range>
            <pub-id pub-id-type="pmid">6393073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dawson</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Cutler</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Hiatt</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Hobson</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Bortey</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Forbes</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Strandness</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>A comparison of cilostazol and pentoxifylline for treating intermittent claudication.</article-title>
            <source>Am J Med</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>109</volume>
            <issue>7</issue>
            <fpage>523</fpage>
            <page-range>523-30</page-range>
            <pub-id pub-id-type="pmid">11063952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guyatt</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Akl</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gutterman</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Schu&#x000fc;nemann</surname>
                <given-names>HJ</given-names>
              </name>
              <collab>American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel</collab>
            </person-group>
            <article-title>Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>7S</fpage>
            <page-range>7S-47S</page-range>
            <pub-id pub-id-type="pmid">22315257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis.</article-title>
            <source>PLoS One</source>
            <year>2022</year>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>e0275392</fpage>
            <pub-id pub-id-type="pmid">36318524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerhard-Herman</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gornik</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barshes</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Corriere</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Drachman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Fowkes</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Hamburg</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Kinlay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lookstein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Misra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mureebe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Olin</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Regensteiner</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Schanzer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shishehbor</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Treat-Jacobson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2017</year>
            <month>Mar</month>
            <day>21</day>
            <volume>135</volume>
            <issue>12</issue>
            <fpage>e686</fpage>
            <page-range>e686-e725</page-range>
            <pub-id pub-id-type="pmid">27840332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jull</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Arroll</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Parag</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline for treating venous leg ulcers.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2012</year>
            <month>Dec</month>
            <day>12</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD001733</fpage>
            <pub-id pub-id-type="pmid">23235582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Houlihan</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2013</year>
            <month>May</month>
            <volume>37</volume>
            <issue>9</issue>
            <fpage>845</fpage>
            <page-range>845-54</page-range>
            <pub-id pub-id-type="pmid">23489011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mellor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sproat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kwok</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cape</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahendran</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The use of liquid formulation pentoxifylline and vitamin E in both established and as a prophylaxis for dental extractions "at risk" of osteoradionecrosis.</article-title>
            <source>Oral Surg Oral Med Oral Pathol Oral Radiol</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>136</volume>
            <issue>4</issue>
            <fpage>404</fpage>
            <page-range>404-409</page-range>
            <pub-id pub-id-type="pmid">37316424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paiva</surname>
                <given-names>GLA</given-names>
              </name>
              <name>
                <surname>de Campos</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Rocha</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>J&#x000fa;nior</surname>
                <given-names>CAL</given-names>
              </name>
              <name>
                <surname>Migliorati</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Dos Santos Silva</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Can the prophylactic use of pentoxifylline and tocopherol before dental extractions prevent osteoradionecrosis? A systematic review.</article-title>
            <source>Oral Surg Oral Med Oral Pathol Oral Radiol</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>136</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-41</page-range>
            <pub-id pub-id-type="pmid">36882364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dissard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>P Dang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barthelemy</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Delbet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Puechmaille</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Depeyre</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Guillemin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Biau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirafzal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mom</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gilain</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Saroul</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of pentoxifylline-tocopherol-clodronate in mandibular osteoradionecrosis.</article-title>
            <source>Laryngoscope</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>130</volume>
            <issue>11</issue>
            <fpage>E559</fpage>
            <page-range>E559-E566</page-range>
            <pub-id pub-id-type="pmid">31747060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clissold</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.</article-title>
            <source>Drugs</source>
            <year>1987</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-97</page-range>
            <pub-id pub-id-type="pmid">3308412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamphuis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smits</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thien</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Vascular effects of pentoxifylline in humans.</article-title>
            <source>J Cardiovasc Pharmacol</source>
            <year>1994</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>648</fpage>
            <page-range>648-54</page-range>
            <pub-id pub-id-type="pmid">7528848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ciuffetti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mercuri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lombardini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paltriccia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lupattelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Santambrogio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mannarino</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1991</year>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>511</fpage>
            <page-range>511-5</page-range>
            <pub-id pub-id-type="pmid">1667754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Mengi</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Arneja</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Dhalla</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.</article-title>
            <source>Exp Clin Cardiol</source>
            <year>2004</year>
            <season>Summer</season>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>103</fpage>
            <page-range>103-11</page-range>
            <pub-id pub-id-type="pmid">19641695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brasileiro</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Inoye</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Aydos</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Falc&#x000e3;o</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Ischemia and reperfusion of rat small intestine using pentoxyfilline and prostaglandin E1.</article-title>
            <source>Acta Cir Bras</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>28</volume>
            <issue>11</issue>
            <fpage>767</fpage>
            <page-range>767-73</page-range>
            <pub-id pub-id-type="pmid">24316743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asvadi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hajipour</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Asvadi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Asl</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Roshangar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Khodadadi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Protective effect of pentoxyfilline in renal toxicity after methotrexate administration.</article-title>
            <source>Eur Rev Med Pharmacol Sci</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>9</issue>
            <fpage>1003</fpage>
            <page-range>1003-9</page-range>
            <pub-id pub-id-type="pmid">22013722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kwiecie&#x00144;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brzozowski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Konturek</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Pawlik</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Pawlik</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Kwiecie&#x00144;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Konturek</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Gastroprotection by pentoxyfilline against stress-induced gastric damage. Role of lipid peroxidation, antioxidizing enzymes and proinflammatory cytokines.</article-title>
            <source>J Physiol Pharmacol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>55</volume>
            <issue>2</issue>
            <fpage>337</fpage>
            <page-range>337-55</page-range>
            <pub-id pub-id-type="pmid">15213357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>NH</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological modulation of TNF production in macrophages.</article-title>
            <source>J Microbiol Immunol Infect</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-15</page-range>
            <pub-id pub-id-type="pmid">15060681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vardareli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Saricam</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koken</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Degirmenci</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Aral</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Erenoglu</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The effect of alpha-tocopherol and pentoxyfilline on ischemia-reperfusion induced liver injury in rats.</article-title>
            <source>Hepatogastroenterology</source>
            <year>1998</year>
            <season>Sep-Oct</season>
            <volume>45</volume>
            <issue>23</issue>
            <fpage>1505</fpage>
            <page-range>1505-8</page-range>
            <pub-id pub-id-type="pmid">9840094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golbasi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Akbas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ozdem</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ukan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ozdem</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Kabuk&#x000e7;u</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Turkay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bayezid</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>The effect of pentoxifylline on haemolysis during cardiopulmonary bypass in open-heart surgery.</article-title>
            <source>Acta Cardiol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-11</page-range>
            <pub-id pub-id-type="pmid">16485727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mansourian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bina</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fehri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karimi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Boroumand</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Abbasi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%).</article-title>
            <source>Anatol J Cardiol</source>
            <year>2015</year>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>1014</fpage>
            <page-range>1014-9</page-range>
            <pub-id pub-id-type="pmid">25880052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sheen</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study.</article-title>
            <source>Diabetol Metab Syndr</source>
            <year>2015</year>
            <volume>7</volume>
            <fpage>64</fpage>
            <pub-id pub-id-type="pmid">26300986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaizova</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Vengerovsky</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Alifirova</surname>
                <given-names>VM</given-names>
              </name>
            </person-group>
            <article-title>[Endothelium-protective effects of vinpocetine, pentoxifylline and enalapril in patients with chronic brain ischemia].</article-title>
            <source>Eksp Klin Farmakol</source>
            <year>2011</year>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>10</fpage>
            <page-range>10-3</page-range>
            <pub-id pub-id-type="pmid">21678652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <article-title>European Pentoxifylline Multi-Infarct Dementia Study.</article-title>
            <source>Eur Neurol</source>
            <year>1996</year>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>315</fpage>
            <page-range>315-21</page-range>
            <pub-id pub-id-type="pmid">8864715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beermann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ings</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>M&#x000e5;nsby</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Kinetics of intravenous and oral pentoxifylline in healthy subjects.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1985</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-8</page-range>
            <pub-id pub-id-type="pmid">3965236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poondru</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Devaraj</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boinpally</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Yamsani</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects.</article-title>
            <source>Pharmacol Res</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>301</fpage>
            <page-range>301-5</page-range>
            <pub-id pub-id-type="pmid">11401423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aviado</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Dettelbach</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication.</article-title>
            <source>Angiology</source>
            <year>1984</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>7</issue>
            <fpage>407</fpage>
            <page-range>407-17</page-range>
            <pub-id pub-id-type="pmid">6380349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Gangopadhyay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dutta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Baksi</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Pani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial.</article-title>
            <source>World J Gastroenterol</source>
            <year>2009</year>
            <month>Apr</month>
            <day>07</day>
            <volume>15</volume>
            <issue>13</issue>
            <fpage>1613</fpage>
            <page-range>1613-9</page-range>
            <pub-id pub-id-type="pmid">19340904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stana</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stergar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gradi&#x00161;nik</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Flis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kargl</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fr&#x000f6;hlich</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stana Kleinschek</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maver</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Multilayered Polysaccharide Nanofilms for Controlled Delivery of Pentoxifylline and Possible Treatment of Chronic Venous Ulceration.</article-title>
            <source>Biomacromolecules</source>
            <year>2017</year>
            <month>Sep</month>
            <day>11</day>
            <volume>18</volume>
            <issue>9</issue>
            <fpage>2732</fpage>
            <page-range>2732-2746</page-range>
            <pub-id pub-id-type="pmid">28776978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hosseini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mohammadbeigi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aghaali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borujerdi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Parham</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effect of pentoxifylline on diabetic distal polyneuropathy in type 2 diabetic patients: A randomized trial.</article-title>
            <source>J Res Med Sci</source>
            <year>2019</year>
            <volume>24</volume>
            <fpage>89</fpage>
            <pub-id pub-id-type="pmid">31741661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furukawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matsubara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Umezawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Motohashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yabuta</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.</article-title>
            <source>Eur J Pediatr</source>
            <year>1994</year>
            <month>Sep</month>
            <volume>153</volume>
            <issue>9</issue>
            <fpage>663</fpage>
            <page-range>663-7</page-range>
            <pub-id pub-id-type="pmid">7957426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Best</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>DeVincenzo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Phelps</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Blumer</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Capparelli</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Connor</surname>
                <given-names>JD</given-names>
              </name>
              <collab>Pediatric Pharmacology Research Unit Network</collab>
            </person-group>
            <article-title>Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease.</article-title>
            <source>Curr Ther Res Clin Exp</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>96</fpage>
            <page-range>96-115</page-range>
            <pub-id pub-id-type="pmid">24944359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yasui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aizawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Komiyama</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of Beh&#x000e7;et disease with pentoxifylline.</article-title>
            <source>Ann Intern Med</source>
            <year>1996</year>
            <month>May</month>
            <day>15</day>
            <volume>124</volume>
            <issue>10</issue>
            <fpage>891</fpage>
            <page-range>891-3</page-range>
            <pub-id pub-id-type="pmid">8610918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sacerdote</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment of homozygous sickle cell disease with pentoxifylline.</article-title>
            <source>J Natl Med Assoc</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>91</volume>
            <issue>8</issue>
            <fpage>466</fpage>
            <page-range>466-70</page-range>
            <pub-id pub-id-type="pmid">12656436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r36">
          <label>36</label>
          <element-citation publication-type="book">
            <chapter-title>Pentoxifylline</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>7</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30000441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plotnikov</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Shamanaev</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Aliev</surname>
                <given-names>OI</given-names>
              </name>
              <name>
                <surname>Sidekhmenova</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Anishchenko</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Arkhipov</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline treatment enhances antihypertensive activity of captopril through hemorheological improvement in spontaneously hypertensive rats during development of arterial hypertension.</article-title>
            <source>J Am Soc Hypertens</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>769</fpage>
            <page-range>769-778</page-range>
            <pub-id pub-id-type="pmid">28989072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Namdar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Khani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pourrashid</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Entezari-Maleki</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Effects of Adding Pentoxifylline to Captopril on Primary Hypertension: A Pilot Randomized Clinical Trial.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-187</page-range>
            <pub-id pub-id-type="pmid">31489650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Cavalcante</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Lucetti</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Menezes</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Felipe</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Alves</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Brito</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Cerqueira</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Viana</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline decreases glycemia levels and TNF-alpha, iNOS and COX-2 expressions in diabetic rat pancreas.</article-title>
            <source>Springerplus</source>
            <year>2014</year>
            <volume>3</volume>
            <fpage>283</fpage>
            <pub-id pub-id-type="pmid">24991532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Hsing</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment.</article-title>
            <source>Sci Rep</source>
            <year>2021</year>
            <month>Jun</month>
            <day>29</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>13521</fpage>
            <pub-id pub-id-type="pmid">34188087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Theophylline.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2013</year>
            <month>Oct</month>
            <day>15</day>
            <volume>188</volume>
            <issue>8</issue>
            <fpage>901</fpage>
            <page-range>901-6</page-range>
            <pub-id pub-id-type="pmid">23672674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leehey</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Reda</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Clise</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Conner</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lammie</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huminik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Polzin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McBurney</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Emanuele</surname>
                <given-names>NV</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial.</article-title>
            <source>BMJ Open</source>
            <year>2021</year>
            <month>Aug</month>
            <day>16</day>
            <volume>11</volume>
            <issue>8</issue>
            <fpage>e053019</fpage>
            <pub-id pub-id-type="pmid">34400461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ran</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of pentoxifylline for chronic venous leg ulcers: study protocol for a multicenter randomized controlled trial in China (ESPECT study).</article-title>
            <source>Trials</source>
            <year>2023</year>
            <month>Aug</month>
            <day>02</day>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>491</fpage>
            <pub-id pub-id-type="pmid">37533132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carballada</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Guiti&#x000e1;n</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nu&#x000f1;ez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pineda</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Boquete</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis due to pentoxifylline.</article-title>
            <source>J Investig Allergol Clin Immunol</source>
            <year>2014</year>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>457</fpage>
            <page-range>457-8</page-range>
            <pub-id pub-id-type="pmid">25668904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salhiyyah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Forster</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Senanayake</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abdel-Hadi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Booth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Michaels</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline for intermittent claudication.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2015</year>
            <month>Sep</month>
            <day>29</day>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>CD005262</fpage>
            <pub-id pub-id-type="pmid">26417854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silver</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kroboth</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline in end-stage renal disease.</article-title>
            <source>Drug Intell Clin Pharm</source>
            <year>1987</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>12</issue>
            <fpage>976</fpage>
            <page-range>976-8</page-range>
            <pub-id pub-id-type="pmid">3428162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eden</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hn-Velten</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kielstein</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of life-threatening pentoxifylline intoxication by high-flux hemodialysis.</article-title>
            <source>Clin Nephrol</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>75</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-3</page-range>
            <pub-id pub-id-type="pmid">21255548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sein Anand</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wiergowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wi&#x0015b;niewski</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kosmowska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wo&#x0017a;niak</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Fatal Suicidal Intoxication with Pentoxifylline Complicated by Cardiovascular Disorders.</article-title>
            <source>Toxics</source>
            <year>2022</year>
            <month>Aug</month>
            <day>03</day>
            <volume>10</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">36006127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107475.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brook-Barclay</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Scicchitano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spark</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Pharmacist influence on prescribing in peripheral arterial disease (PIPER).</article-title>
            <source>Vasc Med</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>118</fpage>
            <page-range>118-124</page-range>
            <pub-id pub-id-type="pmid">24557808</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
